DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contributio
n
Showing posts with label switzerland. Show all posts
Showing posts with label switzerland. Show all posts

Friday, 23 January 2015

Wilma Lukas


Wilma Lukas.jpg

Wilma Lukas, PhD, MBA

Founder & Managing Director at W Life Sciences - Expert Board at Skolkovo Foundation

Dr Lukas has over 20 years of experience in drug discovery, R&D, licensing and business development. Ph.D. in Biology from the Universtity of Geneva, completed by an MBA, she gained pharmaceutical expertise at the Glaxo Institute (GSK) and Serono (now Merck Serono) before joining a start-up that was later on successfully acquired byMolecular Devices Corp (USA).
Dr Lukas joined Debiopharm in 2007. She was in charge of the search and evaluation process and identified pre-clinical and clinical opportunities to in-license in line with Debiopharm’s strategy, business model and portfolio. 
Dr Lukas has created her own consultancy (W Life Sciences) to provide strategic advices and expert scientific opinion to biotech companies, start-ups, universities, investors or pharmaceutical companies. She is supported by expert advisors with more than twenty years of experience in business development and clinical development.

Wilma Lukas, PhD, MBA

Summary

* PhD, MBA, over twenty years experience in the pharmaceutical industry (GSK, Merck Serono, Debiopharm, Molecular Devices)

* Business development, Licensing, Drug Discovery, R&D and Drug Development expertise

Experience





Founder & Managing Director

W Life Sciences
 – Present Geneva Area, Switzerland
- In Licensing: search and identify innovative opportunities
- Out Licensing: search and identify potential partners
- Fund raising
- Mentoring early-stage biotech / start-up companies
- Interim / Part-time business development
- Strategy and positionning
- Market and competition analysis
- Due diligence
- Valuation

- Evaluation of > 1000s opportunities
- All major therapeutic areas, small molecules, biologics, diagnostics

www.wlifesciences.com




Expert Board

Skolkovo Foundation
 – Present (less than a year)Geneva Area, Switzerland




Senior S&E Officer, in Licensing - PhD, MBA

Debiopharm
 –  (3 years)
Drive search and evaluation process of new product opportunities
Identify preclinical and clinical licensing opportunities and companion diagnostics in alignment with company portfolio strategy
Participate and present at international partnering and investor conferences
Discover new areas of innovation and growth opportunities
Perform competitive intelligence and monitor the business environment
Strong network within biotechs, pharmaceutical companies, start-ups, technology transfer centers, bioclusters, science parks, venture capital companies, brokers or governmental organizations




Senior Prospector, PhD, MBA

Debiopharm
 –  (3 years)Switzerland
Drive search and evaluation process of new product opportunities
Identify preclinical and clinical licensing opportunities and companion diagnostics in alignment with company portfolio strategy




Biotech & Pharma Consultant

-
 –  (3 years)
Expertise in Life Sciences, Pharma, New Technologies, Biomedical Devices
Provide scientific support in project evaluation and strategy




Group Leader Biology

Molecular Devices (Cytion)
 –  (2 years)
Development of a new drug screening technology (HTS) for the pharmaceutical industry and academia
Managerial experience in a multicultural environment




Scientist

Merck Serono
 –  (3 years)
Drug discovery and development
Managed cross-functional team in multinational environment




Ass. Scientist

GlaxoSmithKline
 –  (8 years)
R&D in Neurobiology, Physiology, Immunology, Molecular Biology, Biochemistry, Ion channel-related diseases.
Projects management
Scientific publications

Organizations





Swiss HLG (Pharma Licensing Group)

Member
 – Present




HBA (Healthcare Businesswomen's Association)

Member
 – Present




Geneva Pharma Network

Member
 – Present




G.E.I. (Gruppo Esponenti Italiani)

Member
 – Present
Lausanne, Switzerland




Trevisani nel Mondo

President, Lausanne, Switzerland
 – Present

Education




University of Geneva

Ph.D., Biological Sciences

Ph.D. thesis with honors
Two pores potassium channel: structure and function study




IFCAM

Master of Business Administration (MBA)

• Finance
• Accounting
• Law
• Marketing
• Production
• Human Resources
• General Business Administration



Université de Lausanne

MSc Biology

W Life Sciences facilitates strategic relationships, provides advisory services in business development, licensing activities and evaluation of opportunities
Identifying innovation and boosting promissing drug candidates is a must
W Life sciences is an independent consulting firm based in Switzerland
W Life Sciences
Wilma Lukas, PhD, MBA
Managing Director
W Life Sciences
1260 Nyon - Switzerland
Mobile: +41 (0) 79 362 51 91
www.wlifesciences.com
fibers.jpg

Lake_Geneva,_Nyon.JPG

lusanne....below








Skolkovo Foundation

Skolkovo Foundation FIRST ACHIEVEMENTS. 2010—2011Creatingin Skolkovo The foundation expert network: Berkley, Russian and International Skolkovo Innovation ...





DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE


Join me on Linkedin

View Anthony Melvin Crasto Ph.D's profile on LinkedIn

Join me on Facebook FACEBOOK
Join me on twitterFollow amcrasto on Twitter     
Join me on google plus Googleplus

 amcrasto@gmail.com


Tuesday, 6 January 2015

Prof. Dr. Jürg Hulliger

Prof. Dr. Jürg Hulliger
Department of Chemistry & Biochemistry
University of Bern
Freiestrasse 3
CH-3012 Bern, 
Switzerland
+4131 6314241
+4131 6314272
juerg.hulliger@iac.unibe.ch
University of Berne





Map of university of bern

Background
1953Born
1978Diploma thesis, ETH Zürich, Switzerland
1984Doctoral thesis, University of Zürich, Switzerland
1985-1986Postdoctoral fellowship (NF), Pennsylvania State University, USA
1987-1993Senior research scientist, Institute of Quantum Electronics, ETH Zürich
1993 - presentProfessor of Materials Chemistry, University of Bern, Switzerland
2004 - presentFellow of the Royal Society of Chemistry
2005 - 2009Project leader of Project 4, NCCR MaNEP II

 



Research Topics




Stochastic Theory of Growth Induced Polarity in Various Types of Materials
Channel-type Inclusion Compounds
and Organic Zeolites
Experimental Investigation of Polar Properties of Molecular Crystals






Combinatorial Chemistry on the Basis
of a Single Sample Concept
Magnetic Separation Technique
in Solid State Chemistry
Synthesis and Crystal Engineering
of Polyfluorinated Aromatics

Publication list


1.                  J. Hulliger
Chemistry and crystal growth
Angew. Chem. Int. Ed. Engl., 33, 143-162, 1994

2.                  O. König, R. Hoss, J. Hulliger
Polare molekulare Kanaleinschlussgitter
Z. Kristallogr. Suppl.9, 90, 1994

3.                  J. Hulliger, O. König, R. Hoss
Polar inclusion compounds of perhydrotriphenylene and efficient nonlinear optical molecules
Adv. Mater., 7, 719-721, 1995

4.                  J. Hulliger, O. König, P. Rogin, P. Rechsteiner, A. Ritzi, P.J. Langley
Organic photorefractive materials: a new structural approach
Proc. SPIE2850, 54-62, 1996

5.                  O. König, U. Berger, J. Hulliger
Channel-type inclusion lattices of perhydrotriphenylene: a new route to efficient organic electro-optical materials
Proc. SPIE2852, 23-31, 1996

6.                  M.S. Wickleder, P. Egger, T. Riedener, N. Furer, H.U. Güdel, J. Hulliger
Synthesis and crystal structure of the new ternary halide series Ba2MCl7 : (M = Gd-Yb, Y) containing the highly efficient up-conversion material Ba2ErCl7
Chem. Mater.8, 2828-2831, 1996

7.                  J. Hulliger, O. König, V. Kramer-Hoss
Crystal growth and characterization of NLO-active organic inclusion compounds
Acta Cryst. A52, C511, 1996

8.                  M.S. Wickleder, P. Egger, J. Hulliger
Ba2ErCl7: a new ternary rare earth chloride with barium
Acta Cryst. A52, C392, 1996

9.                  O. König, H.-B. Bürgi, T. Armbruster, J. Hulliger
Disorder and diffuse scattering of channel type inclusion compounds with perhydrotriphenylene
Acta Cryst. A52, C376, 1996

10.              P. Egger, P. Rogin, T. Riedener, H.U. Güdel, M. Wickleder, J. Hulliger
Ba2ErCl7 - a new near IR to UV upconversion material
Adv. Mater.8, 668-672, 1996

Freiestrasse 3. CH-3012 Bern Switzerland. Department of Chemistry and Biochemistry
 


 

 








Head of the group
Phone: +41(0)31 631 42 41
Fax: +41(0)31 631 42 72

Secretary
Phone: +41(0)31 631 43 61
Fax: +41(0)31 631 42 72

Postal address
Universität Bern
Gruppe Hulliger
Department für Chemie & Biochemie
Freiestrasse 3 BERN
<!-Local Time Clock widget - HTML code - localtimes.info -->

<!-end of code-->






DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Join me on Linkedin

View Anthony Melvin Crasto Ph.D's profile on LinkedIn

Join me on Facebook FACEBOOK
Join me on twitterFollow amcrasto on Twitter     
Join me on google plus Googleplus

 amcrasto@gmail.com